Bio NTech RNA Pharmaceuticals

GPTKB entity

Statements (61)
Predicate Object
gptkbp:instance_of gptkb:biotechnology
gptkbp:accessories gptkb:European_Commission
gptkbp:acquisition Pfizer partnership
gptkbp:awards European Inventor Award 2021
gptkbp:ceo gptkb:Ozlem_Tureci
gptkb:Uğur_Şahin
gptkbp:clinical_trial gptkb:Germany
Phase 1
Phase 2
Phase 3
44,000
gptkbp:collaborates_with gptkb:Fosun_Pharma
gptkbp:collaboration gptkb:Sanofi
gptkb:Moderna
gptkbp:collaborations gptkb:Harvard_University
gptkb:National_Institutes_of_Health
gptkbp:community_impact gptkb:COVID-19_pandemic
gptkbp:focus m RNA technology
gptkbp:founded gptkb:2008
gptkbp:founder gptkb:Uğur_Şahin
gptkbp:funding $2 billion (2021)
gptkbp:headquarters gptkb:Mainz,_Germany
https://www.w3.org/2000/01/rdf-schema#label Bio NTech RNA Pharmaceuticals
gptkbp:invention m RNA technology patents
gptkbp:investment $1.5 billion (2020)
gptkbp:is_a_platform_for m RNA-based therapeutics
gptkbp:is_vulnerable_to gptkb:BNT162b2
gptkb:significant
gptkb:FDA
gptkb:vaccine
gptkb:Comirnaty
95%
December 2020
global
ongoing
monitored
intramuscular injection
less than a year
-70° C
gptkbp:number_of_employees over 1,000
gptkbp:partnership gptkb:Pfizer
gptkb:Cure_Vac
gptkbp:product gptkb:BNT162b2
gptkbp:publications gptkb:Nature
gptkbp:research_areas gptkb:immunotherapy
infectious diseases
gptkbp:research_focus cancer vaccines
gptkbp:revenue $18.9 billion (2021)
gptkbp:stock_exchange gptkb:NASDAQ
gptkbp:stock_symbol gptkb:BNTX
gptkbp:type_of_vaccine gptkb:vaccine
gptkbp:vaccine_approval_authority gptkb:EMA
gptkbp:vaccine_clinical_trial successful
gptkbp:vaccine_distribution_partnership gptkb:UPS
gptkbp:vaccine_doses 2 doses
gptkbp:vaccine_efficacy_rate high
gptkbp:vaccine_production Germany and Belgium
gptkbp:vaccine_storage_temperature -80° C to -60° C
gptkbp:vaccine_target gptkb:SARS-Co_V-2
gptkbp:bfsParent gptkb:Bio_NTech
gptkbp:bfsLayer 5